Last reviewed 2026-04-20 · How we verify

Epodyl (ETOGLUCID)

Phase 2 active Small molecule

Epodyl (generic name: ETOGLUCID) is a etoglucid drug. It is currently in Phase 2 development.

Epodyl works by inhibiting the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is involved in cellular energy production.

Epodyl (EtoGluclid) is a small molecule etoglucid, a drug class with unknown target. It is currently owned by an unknown entity, with unknown FDA approval status. Epodyl is used to treat unknown indications, and its commercial status is unknown. Key safety considerations are also unknown. As a small molecule, Epodyl works by interacting with its target to produce a therapeutic effect.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOGLUCID
Drug class	etoglucid
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of Epodyl like a brake on a car engine. By inhibiting GAPDH, Epodyl slows down the engine's fuel consumption, which can help reduce inflammation and other cellular processes that contribute to disease. This can lead to therapeutic benefits in various conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Epodyl CI brief — competitive landscape report
Epodyl updates RSS · CI watch RSS

Frequently asked questions about Epodyl

What is Epodyl?

Epodyl (ETOGLUCID) is a etoglucid drug.

How does Epodyl work?

Epodyl works by inhibiting the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which is involved in cellular energy production.

What is the generic name of Epodyl?

ETOGLUCID is the generic (nonproprietary) name of Epodyl.

What drug class is Epodyl in?

Epodyl belongs to the etoglucid class. See all etoglucid drugs at /class/etoglucid.

What development phase is Epodyl in?

Epodyl is in Phase 2.

Drug class: All etoglucid drugs
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing